Research Article
Effect of Neutrophil-to-Lymphocyte Ratio on Post-TAVR Mortality and Periprocedural Pulmonary Hypertension
Table 2
The prediction of pre- and post-TAVR pulmonary hypertension.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TAVR, transcatheter aortic valve replacement; PH, pulmonary hypertension; BMI, body mass index; HB, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-lymphocyte-ratio; RDW_SD, the red cell distribution width_Standard Deviation; BNP, B-type natriuretic peptide; TG, triglyceride; UA, uric acid; ALT, alanine aminotransferase; T-BIL, serum total bilirubin; r-GT, r-glutamyltranspeptidase; RVD, right ventricular diastolic diameter; LAVI, left atrial volume index; PAD, pulmonary artery diameter; LVEF, left ventricular ejection fraction; E/e′, early diastolic transmitral flow velocity/lateral mitral annular myocardial velocity; AV, aortic valve. , vs. No PH. The bold values indicate statistical significances (). |